Medical Developments International (FRA:M5D) Piotroski F-Score: 5 (As of Jun. 26, 2026) — Near Median


FRA:M5D Medical Developments International Ltd FRA:M5D
32 GF Score
Price €0.20
GF Value €0.35
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medical Developments International Piotroski F-Score?

Medical Developments International FRA:M5D +1.55% 32 Piotroski F-Score is 5 as of Jun. 26, 2026, which is at its 10-year median of 5.00. GuruFocus rates FRA:M5D with a GF Score™ of 32/100 and a GF Value™ of €0.35 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 981 Drug Manufacturers companies, Medical Developments International ranks better than 61.37% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Medical Developments International has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Medical Developments International's Piotroski F-Score or its related term are showing as below:

FRA:M5D' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of Medical Developments International was 7. The lowest was 2. And the median was 5.

Medical Developments International  (FRA:M5D) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Medical Developments International Piotroski F-Score Related Terms


Medical Developments International Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Medical Developments International's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medical Developments International Piotroski F-Score Chart

Medical Developments International Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 3.00 3.00 2.00 5.00

Medical Developments International Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.00 0.00 5.00 0.00

FRA:M5D vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medical Developments International Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Medical Developments International's Piotroski F-Score falls into.


FRA:M5D
32GF Score
Medical Developments International Ltd FRA:M5D
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun25) TTM:Last Year (Jun24) TTM:
Net Income was €0.05 Mil.
Cash Flow from Operations was €-0.02 Mil.
Revenue was €22.05 Mil.
Gross Profit was €16.61 Mil.
Average Total Assets from the begining of this year (Jun24)
to the end of this year (Jun25) was (36.494 + 37.477) / 2 = €36.9855 Mil.
Total Assets at the begining of this year (Jun24) was €36.49 Mil.
Long-Term Debt & Capital Lease Obligation was €0.94 Mil.
Total Current Assets was €20.06 Mil.
Total Current Liabilities was €4.42 Mil.
Net Income was €-25.29 Mil.

Revenue was €20.45 Mil.
Gross Profit was €15.03 Mil.
Average Total Assets from the begining of last year (Jun23)
to the end of last year (Jun24) was (62.76 + 36.494) / 2 = €49.627 Mil.
Total Assets at the begining of last year (Jun23) was €62.76 Mil.
Long-Term Debt & Capital Lease Obligation was €1.18 Mil.
Total Current Assets was €16.13 Mil.
Total Current Liabilities was €5.89 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Medical Developments International's current Net Income (TTM) was 0.05. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Medical Developments International's current Cash Flow from Operations (TTM) was -0.02. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun24)
=0.053/36.494
=0.00145229

ROA (Last Year)=Net Income/Total Assets (Jun23)
=-25.287/62.76
=-0.40291587

Medical Developments International's return on assets of this year was 0.00145229. Medical Developments International's return on assets of last year was -0.40291587. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Medical Developments International's current Net Income (TTM) was 0.05. Medical Developments International's current Cash Flow from Operations (TTM) was -0.02. ==> -0.02 <= 0.05 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=0.943/36.9855
=0.02549648

Gearing (Last Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=1.181/49.627
=0.02379753

Medical Developments International's gearing of this year was 0.02549648. Medical Developments International's gearing of last year was 0.02379753. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun25)=Total Current Assets/Total Current Liabilities
=20.061/4.416
=4.54279891

Current Ratio (Last Year: Jun24)=Total Current Assets/Total Current Liabilities
=16.126/5.889
=2.73832569

Medical Developments International's current ratio of this year was 4.54279891. Medical Developments International's current ratio of last year was 2.73832569. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Medical Developments International's number of shares in issue this year was 109.992. Medical Developments International's number of shares in issue last year was 88.602. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=16.61/22.045
=0.75345883

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=15.031/20.448
=0.73508412

Medical Developments International's gross margin of this year was 0.75345883. Medical Developments International's gross margin of last year was 0.73508412. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun24)
=22.045/36.494
=0.6040719

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun23)
=20.448/62.76
=0.32581262

Medical Developments International's asset turnover of this year was 0.6040719. Medical Developments International's asset turnover of last year was 0.32581262. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+0+1+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Medical Developments International has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Medical Developments International (FRA:M5D) has a Piotroski F-Score of 5 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Medical Developments International and its competitors. This is near median its historical median of 5.00. Over the past decade, Medical Developments International's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Medical Developments International ranks #379 out of 981 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is Medical Developments International's Piotroski F-Score too high?
Medical Developments International's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Medical Developments International's value of 5 is 0% at this industry median. Based on the distribution chart, Medical Developments International ranks #379 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medical Developments International has a GF Score™ of 32/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #379 out of 981 companies for Piotroski F-Score. This puts Medical Developments International in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Medical Developments International's value of 5 is 0% at this benchmark. Historically, Medical Developments International's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Medical Developments International has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (FRA:M5D) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.35, compared to a current price of €0.20 — trading 43.7% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Drug Manufacturers industry median of 5.00. Medical Developments International's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Medical Developments International (FRA:M5D), the current Piotroski F-Score is 5 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medical Developments International (FRA:M5D) Overvalued in 2026?

Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued. The current stock price of €0.20 is trading 43.7% below its estimated GF Value™ of €0.35. GuruFocus considers Medical Developments International to be Significantly Undervalued.

Key valuation signals for FRA:M5D:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: €0.35 vs. price of €0.20 (43.7% below fair value)
  • GF Score™: 32/100 with 2 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#379 of 981)

No single metric tells the full story. See the FRA:M5D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medical Developments International Business Description

Other Exchanges MDDVF:USAMVP:Australia
Address 4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
32GF Score

Get the complete analysis for FRA:M5D

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.35
GF Value